Psyence Biomedical (PBM) Competitors $3.18 +0.72 (+29.27%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PBM vs. EDSA, ONVO, AIMD, CNSP, SYRS, HOTH, GTBP, ELAB, IMCC, and CANFShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Edesa Biotech (EDSA), Organovo (ONVO), Ainos (AIMD), CNS Pharmaceuticals (CNSP), Syros Pharmaceuticals (SYRS), Hoth Therapeutics (HOTH), GT Biopharma (GTBP), Elevai Labs (ELAB), IM Cannabis (IMCC), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Edesa Biotech Organovo Ainos CNS Pharmaceuticals Syros Pharmaceuticals Hoth Therapeutics GT Biopharma Elevai Labs IM Cannabis Can-Fite BioPharma Edesa Biotech (NASDAQ:EDSA) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations. Does the MarketBeat Community prefer EDSA or PBM? Edesa Biotech received 27 more outperform votes than Psyence Biomedical when rated by MarketBeat users. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Psyence BiomedicalN/AN/A Do institutionals and insiders believe in EDSA or PBM? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, EDSA or PBM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$8.37M-$1.93-0.90Psyence BiomedicalN/AN/A-$51.16MN/AN/A Do analysts rate EDSA or PBM? Edesa Biotech currently has a consensus price target of $21.00, suggesting a potential upside of 1,113.87%. Given Edesa Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Edesa Biotech is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer EDSA or PBM? In the previous week, Psyence Biomedical had 5 more articles in the media than Edesa Biotech. MarketBeat recorded 6 mentions for Psyence Biomedical and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 0.80 beat Psyence Biomedical's score of 0.43 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Psyence Biomedical 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, EDSA or PBM? Edesa Biotech has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.57, suggesting that its stock price is 157% less volatile than the S&P 500. Is EDSA or PBM more profitable? Psyence Biomedical's return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -137.95% -97.48% Psyence Biomedical N/A N/A N/A SummaryEdesa Biotech beats Psyence Biomedical on 8 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.68M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book-0.055.094.784.78Net Income-$51.16M$151.83M$120.31M$225.60M7 Day Performance71.89%-2.14%-1.92%-1.23%1 Month Performance-2.53%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence BiomedicalN/A$3.18+29.3%N/AN/A$2.68MN/A0.00N/ANews CoveragePositive NewsGap UpHigh Trading VolumeEDSAEdesa Biotech3.5595 of 5 stars$1.92-1.0%$21.00+993.8%-64.1%$6.24MN/A-1.0020Earnings ReportPositive NewsGap DownHigh Trading VolumeONVOOrganovoN/A$0.39-2.5%N/A-67.6%$6.03M$110,000.000.0020Analyst ForecastAIMDAinosN/A$0.43-2.3%N/A-80.1%$5.95M$120,000.000.0046Gap DownCNSPCNS Pharmaceuticals1.2211 of 5 stars$0.10flat$0.50+385.4%-99.8%$5.92MN/A0.005Gap DownSYRSSyros Pharmaceuticals4.2571 of 5 stars$0.22+4.8%$3.33+1,415.2%-96.5%$5.90M$386,000.00-0.07120Gap UpHOTHHoth Therapeutics2.0095 of 5 stars$0.83+2.5%$3.50+323.2%-30.8%$5.71MN/A-0.634Gap UpGTBPGT Biopharma3.6544 of 5 stars$2.51-8.7%$11.00+338.2%-78.3%$5.61MN/A0.008Positive NewsGap UpELABElevai Labs0.3441 of 5 stars$2.06-10.0%N/A-99.3%$5.33M$2.45M-0.0318News CoverageGap DownIMCCIM Cannabis0.0474 of 5 stars$2.38-3.6%N/A+3.4%$5.31M$51.39M-0.72340Gap DownCANFCan-Fite BioPharma1.7922 of 5 stars$1.50-5.1%$14.00+833.3%-30.7%$5.31M$667,000.00-0.848 Related Companies and Tools Related Companies Edesa Biotech Alternatives Organovo Alternatives Ainos Alternatives CNS Pharmaceuticals Alternatives Syros Pharmaceuticals Alternatives Hoth Therapeutics Alternatives GT Biopharma Alternatives Elevai Labs Alternatives IM Cannabis Alternatives Can-Fite BioPharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
